Category Research

Octave

Octave Bioscience’s MSDA Test Demonstrates Clinically Actionable Insights for Improved MS Care Decisions

Octave Bioscience’s MSDA Test Demonstrates Clinically Actionable Insights for Improved MS Care Decisions In a significant advancement for the field of neurodegenerative disease management, Octave Bioscience, Inc., a precision care company focused on transforming how multiple sclerosis (MS) and other…

Read MoreOctave Bioscience’s MSDA Test Demonstrates Clinically Actionable Insights for Improved MS Care Decisions
Eyestem

Eyestem’s Eyecyte-RPE™ Demonstrates Vision Preservation in Geographic Atrophy Clinical Trial

Eyestem’s Eyecyte-RPE™ Demonstrates Vision Preservation in Geographic Atrophy Clinical Trial Bangalore-based biotech firm Eyestem Research has reported highly encouraging results from its Phase 1 clinical trial evaluating Eyecyte-RPE™, a novel investigational cell therapy aimed at treating geographic atrophy (GA) secondary…

Read MoreEyestem’s Eyecyte-RPE™ Demonstrates Vision Preservation in Geographic Atrophy Clinical Trial
Pill Penalty

New Study Exposes Harmful Effects of IRA’s ‘Pill Penalty’ on Small Molecule Drugs

New Study Exposes Harmful Effects of IRA’s ‘Pill Penalty’ on Small Molecule Drugs A recently published peer-reviewed study is shedding light on the unintended yet far-reaching consequences of the Inflation Reduction Act (IRA) on the U.S. biopharmaceutical sector—particularly in the…

Read MoreNew Study Exposes Harmful Effects of IRA’s ‘Pill Penalty’ on Small Molecule Drugs
Exicure

Exicure Approaches Phase 2 Completion for GPC-100 in Multiple Myeloma Treatment

Exicure Approaches Phase 2 Completion for GPC-100 in Multiple Myeloma Treatment Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company advancing novel small molecule therapeutics for immuno-oncology and hematological malignancies, announced a significant milestone today in its ongoing Phase 2 clinical…

Read MoreExicure Approaches Phase 2 Completion for GPC-100 in Multiple Myeloma Treatment
Exicure

Exicure Announces Plans for New Clinical Trial in Acute Myeloid Leukemia (AML)

Exicure Announces Plans for New Clinical Trial in Acute Myeloid Leukemia (AML) Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company focused on developing innovative therapeutics targeting diseases with high unmet medical needs, announced significant updates today regarding its lead investigational…

Read MoreExicure Announces Plans for New Clinical Trial in Acute Myeloid Leukemia (AML)
Pregnancy

Biologic Therapy Boosts Pregnancy Outcomes in High-Risk APS Patients

Biologic Therapy Boosts Pregnancy Outcomes in High-Risk APS Patients Landmark Clinical Trial Finds Certolizumab Significantly Improves Pregnancy Outcomes in Women with Antiphospholipid Syndrome In a groundbreaking advancement for maternal-fetal medicine and autoimmune disease treatment, a phase 2 clinical trial co-led…

Read MoreBiologic Therapy Boosts Pregnancy Outcomes in High-Risk APS Patients
Antibiotic

Two Major Trials Identify Effective Antibiotic Selection Method for Hospitalized Infection Patients

Two Major Trials Identify Effective Antibiotic Selection Method for Hospitalized Infection Patients In a significant advancement for infectious disease care and antibiotic stewardship, two large-scale clinical trials funded by the National Institutes of Health (NIH) have demonstrated that integrating real-time,…

Read MoreTwo Major Trials Identify Effective Antibiotic Selection Method for Hospitalized Infection Patients
LifeMine

LifeMine Doses First Participant in Phase 1 Trial of Novel Immunosuppressive LIFE-001

LifeMine Doses First Participant in Phase 1 Trial of Novel Immunosuppressive LIFE-001 LifeMine Therapeutics Inc., a clinical-stage biopharmaceutical company redefining small molecule discovery through its proprietary genomic search platform, has officially dosed the first participant in a Phase 1 clinical…

Read MoreLifeMine Doses First Participant in Phase 1 Trial of Novel Immunosuppressive LIFE-001